Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Analyst Ratings
Moderate Buy
9 Buy
7 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MRK Stock 12 Month Forecast
Average Price Target
$101.93
▲(21.24% Upside)
| Highest Price Target$141.00 | Average Price Target$101.93 | Lowest Price Target$82.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$107
Buy
27.27%
Upside
Reiterated
08/26/25
Goldman Sachs
$94
Buy
11.81%
Upside
Reiterated
08/19/25
Merck & Co.'s Strategic Positioning and Market Potential Justify Buy Rating Despite ChallengesWe note these actions follow the recent company’s price-promotion initiatives since May where it is providing a free last shot of Gardasil in different age groups (free second dose to 9-14 year-old recipients in a few provinces, and free third dose in 15-45 year-old group) an effort to continue to wind down excess inventory. Our Zhifei analyst now estimates 20% ASP decline from such promotions and further revises down sales and volume projections for Gardasil in 2025E, though notes positive trends with respect to ongoing the inventory impairment. As a reminder, alongside its 2Q25 earnings, MRK again pushed out its expectations for an inflection in China Gardasil, noting it plans no shipments at least through the end of this year, citing elevated inventories and soft demand.
Bernstein
―
Hold
―
Reiterated
08/17/25
TR | OpenAI - 4o
$95→$96
Buy
14.19%
Upside
Reiterated
08/14/25
Unknown Analyst
Berenberg BankNot Ranked
Berenberg Bank
$100
Buy
18.95%
Upside
Reiterated
08/11/25
BMO Capital
$82
Hold
-2.46%
Downside
Reiterated
08/04/25
Wells Fargo
$97→$90
Hold
7.05%
Upside
Reiterated
07/30/25
J.P. Morgan
$130→$120
Buy
42.74%
Upside
Reiterated
07/30/25
Cantor Fitzgerald
$83
Hold
-1.27%
Downside
Reiterated
07/29/25
Bank of America Securities
$99
Buy
17.76%
Upside
Reiterated
07/23/25
Guggenheim
$108
Buy
28.46%
Upside
Reiterated
07/13/25
UBS
$105
Buy
24.90%
Upside
Reiterated
07/10/25
Jefferies
$138→$141
Buy
67.72%
Upside
Reiterated
07/10/25
Morgan Stanley
$99→$98
Hold
16.57%
Upside
Reiterated
07/10/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$107
Buy
27.27%
Upside
Reiterated
08/26/25
Goldman Sachs
$94
Buy
11.81%
Upside
Reiterated
08/19/25
Merck & Co.'s Strategic Positioning and Market Potential Justify Buy Rating Despite ChallengesWe note these actions follow the recent company’s price-promotion initiatives since May where it is providing a free last shot of Gardasil in different age groups (free second dose to 9-14 year-old recipients in a few provinces, and free third dose in 15-45 year-old group) an effort to continue to wind down excess inventory. Our Zhifei analyst now estimates 20% ASP decline from such promotions and further revises down sales and volume projections for Gardasil in 2025E, though notes positive trends with respect to ongoing the inventory impairment. As a reminder, alongside its 2Q25 earnings, MRK again pushed out its expectations for an inflection in China Gardasil, noting it plans no shipments at least through the end of this year, citing elevated inventories and soft demand.
Bernstein
―
Hold
―
Reiterated
08/17/25
TR | OpenAI - 4o
$95→$96
Buy
14.19%
Upside
Reiterated
08/14/25
Unknown Analyst
Berenberg BankNot Ranked
Berenberg Bank
$100
Buy
18.95%
Upside
Reiterated
08/11/25
BMO Capital
$82
Hold
-2.46%
Downside
Reiterated
08/04/25
Wells Fargo
$97→$90
Hold
7.05%
Upside
Reiterated
07/30/25
J.P. Morgan
$130→$120
Buy
42.74%
Upside
Reiterated
07/30/25
Cantor Fitzgerald
$83
Hold
-1.27%
Downside
Reiterated
07/29/25
Bank of America Securities
$99
Buy
17.76%
Upside
Reiterated
07/23/25
Guggenheim
$108
Buy
28.46%
Upside
Reiterated
07/13/25
UBS
$105
Buy
24.90%
Upside
Reiterated
07/10/25
Jefferies
$138→$141
Buy
67.72%
Upside
Reiterated
07/10/25
Morgan Stanley
$99→$98
Hold
16.57%
Upside
Reiterated
07/10/25
Best Analysts Covering Merck & Company
1 Month
xxx
Success Rate
10/14 ratings generated profit
Average Return
+1.53%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +1.53% per trade.
3 Months
xxx
Success Rate
10/14 ratings generated profit
Average Return
+3.24%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +3.24% per trade.
1 Year
Success Rate
9/14 ratings generated profit
Average Return
+5.98%
reiterated a buy rating last month
Copying Tim Anderson's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +5.98% per trade.
2 Years
xxx
Success Rate
15/18 ratings generated profit
Average Return
+13.19%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +13.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MRK Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
2
2
3
4
3
Buy
29
22
25
24
24
Hold
19
15
26
27
24
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
50
39
55
56
52
Each month's total comprises the sum of three months' worth of ratings.
MRK Financial Forecast
MRK Stock Forecast FAQ
What is MRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is 101.93.
What is MRK’s upside potential, based on the analysts’ average price target?
Merck & Company has 21.24% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MRK a Buy, Sell or Hold?
Merck & Company has a consensus rating of Moderate Buy which is based on 9 buy ratings, 7 hold ratings and 0 sell ratings.
What is Merck & Company’s price target?
The average price target for Merck & Company is 101.93. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $141.00 ,the lowest forecast is $82.00. The average price target represents 21.24% Increase from the current price of $84.07.
The highest analyst price target is $141.00 ,the lowest forecast is $82.00. The average price target represents 21.24% Increase from the current price of $84.07.
What do analysts say about Merck & Company?
Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of MRK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.